Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Atsuo Takashima et al.|The Lancet Oncology|2024Cited by 124
Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2Hwang‐Phill Kim, Tae‐You Kim|PLoS ONE|2009Cited by 116
Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancersJiyeon Yun, Tae‐You Kim|Laboratory Investigation|2012Cited by 43